IRIS
GENTILE, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 9.362
NA - Nord America 4.944
SA - Sud America 2.948
EU - Europa 2.351
AF - Africa 418
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 4
AN - Antartide 1
Totale 20.037
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.612
SG - Singapore 3.824
BR - Brasile 2.152
CN - Cina 1.809
VN - Vietnam 1.739
IT - Italia 805
FR - Francia 395
HK - Hong Kong 394
KR - Corea 315
AR - Argentina 287
DE - Germania 227
BD - Bangladesh 221
FI - Finlandia 183
IN - India 176
IQ - Iraq 156
MX - Messico 148
EC - Ecuador 126
GB - Regno Unito 117
RU - Federazione Russa 112
ZA - Sudafrica 108
NL - Olanda 106
CO - Colombia 96
ID - Indonesia 86
PK - Pakistan 80
VE - Venezuela 80
CA - Canada 74
TR - Turchia 73
MA - Marocco 71
AT - Austria 70
UA - Ucraina 69
CL - Cile 64
UZ - Uzbekistan 58
PY - Paraguay 54
DZ - Algeria 42
PH - Filippine 42
SA - Arabia Saudita 42
JO - Giordania 40
EG - Egitto 38
PL - Polonia 38
TN - Tunisia 36
ES - Italia 35
UY - Uruguay 34
MY - Malesia 31
PE - Perù 28
SE - Svezia 27
BO - Bolivia 26
JP - Giappone 26
KE - Kenya 26
KZ - Kazakistan 25
NP - Nepal 25
AZ - Azerbaigian 24
AE - Emirati Arabi Uniti 23
SN - Senegal 22
IL - Israele 21
CZ - Repubblica Ceca 20
KG - Kirghizistan 20
CR - Costa Rica 19
DO - Repubblica Dominicana 19
PA - Panama 18
ET - Etiopia 17
OM - Oman 17
AL - Albania 15
BG - Bulgaria 14
LB - Libano 14
GT - Guatemala 13
PS - Palestinian Territory 12
JM - Giamaica 11
RO - Romania 11
RS - Serbia 11
TH - Thailandia 11
BA - Bosnia-Erzegovina 10
QA - Qatar 10
HN - Honduras 9
NG - Nigeria 9
AO - Angola 8
IE - Irlanda 8
SK - Slovacchia (Repubblica Slovacca) 8
HU - Ungheria 7
NI - Nicaragua 7
SY - Repubblica araba siriana 7
AU - Australia 6
BE - Belgio 6
BH - Bahrain 6
BY - Bielorussia 6
CI - Costa d'Avorio 6
GE - Georgia 6
GR - Grecia 6
HR - Croazia 6
KW - Kuwait 6
LT - Lituania 6
MU - Mauritius 5
CH - Svizzera 4
GA - Gabon 4
KH - Cambogia 4
LY - Libia 4
MK - Macedonia 4
NO - Norvegia 4
PT - Portogallo 4
SC - Seychelles 4
TT - Trinidad e Tobago 4
Totale 19.964
Salva come PNG Salva come JPEG
Città #
Singapore 1.469
San Jose 1.115
Dallas 740
Boardman 650
Ho Chi Minh City 645
Ashburn 517
Hefei 510
Hong Kong 389
Hanoi 361
Beijing 325
Florence 315
Seoul 313
Lauterbourg 306
Shanghai 226
São Paulo 188
Helsinki 137
Los Angeles 98
Da Nang 92
Haiphong 92
Munich 83
Council Bluffs 73
Rio de Janeiro 72
New York 69
Ogden 68
Santa Clara 64
Guangzhou 59
Boydton 55
Amsterdam 51
Baghdad 51
Quito 51
Tashkent 50
Dhaka 49
Sesto Fiorentino 47
Brasília 46
Noto 45
Vienna 45
Biên Hòa 41
Belo Horizonte 39
Brooklyn 39
Johannesburg 37
Amman 35
Frankfurt am Main 35
Mexico City 33
Tianjin 32
Guayaquil 31
Milan 30
Warsaw 30
Montreal 29
Buenos Aires 28
Caracas 28
Rome 28
Curitiba 27
Orem 27
Porto Alegre 27
The Dalles 27
Wuhan 27
Asunción 26
Hải Dương 26
Lahore 26
Montevideo 26
Santiago 25
Thái Nguyên 25
Ninh Bình 24
Turku 24
Can Tho 23
Tokyo 23
Campinas 22
Dakar 22
Fortaleza 22
Atlanta 21
Bogotá 21
Chennai 21
Erbil 21
Lappeenranta 21
Nairobi 21
Stockholm 21
Chicago 20
London 20
Washington 20
Baku 19
Chandler 19
Guarulhos 19
Nuremberg 19
Phoenix 19
Recife 19
Rende 19
Salvador 19
San Francisco 19
Cape Town 18
Casablanca 18
Falkenstein 18
Medellín 18
Santo André 18
Secaucus 18
Addis Ababa 17
Boston 17
Charlotte 17
Istanbul 17
Seattle 17
Ribeirão Preto 16
Totale 10.997
Salva come PNG Salva come JPEG
Nome #
CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy 163
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? 161
Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study 156
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity 150
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 124
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 121
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma 119
A novel phage display based platform for exosome diversity characterization 118
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 116
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 114
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 113
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies 112
The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients 110
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 108
Momelotinib in myelofibrosis 108
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 107
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 105
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 104
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 104
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Successfully Treated with Rituximab-Venetoclax: A Case Report 104
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? 103
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 103
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 102
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 100
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 100
TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions 99
Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay 98
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study 97
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 97
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 97
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells 96
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 96
Vaccination in Multiple Myeloma: Challenges and Strategies 96
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 96
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement 96
Belantamab mafodotin in multiple myeloma 96
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 94
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience 94
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 93
Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax 93
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 92
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study 92
Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking? 92
A progression-risk score to predict treatment free survival for early stage chronic lymphocytic leukemia patients. 91
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. 91
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 90
Iron chelation therapy 90
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 90
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 89
A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL) 87
Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. 87
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement 87
Ibrutinib in patients over 80 with chronic lymphocytic leukemia: a multicenter Italian cohort 87
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives 86
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement 86
Elotuzumab in multiple myeloma 85
Acalabrutinib in chronic lymphocytic leukemia 84
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 83
Mitochondrial fission factor drives an actionable metabolic vulnerability in multiple myeloma 83
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? 83
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells 82
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study 82
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature 81
Predominant VH1-69 IgBCR Clones Show Higher Expression of CD5 in Heterogeneous Chronic Lymphocytic Leukemia Populations 81
The use of ibrutinib before and after allogeneic stem cell transplantation 80
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study 80
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 80
Cerebral pheohyphomycosis due to curvularia species 79
Ivosidenib in acute myeloid leukemia 79
Selinexor in multiple myeloma 79
Teclistamab-cqyv in multiple myeloma 79
Rilzabrutinib for the Treatment of Immune Thrombocytopenia 78
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 78
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 77
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study 77
Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms 77
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing 77
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 77
Myelodysplastic syndromes with ring sideroblasts 76
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 76
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 76
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 75
A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. 75
Comparative Analysis of Bispecific Antibodies and CAR T‐Cell Therapy in Follicular Lymphoma 75
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant 75
An old drug with a new future: bendamustine in multiple myeloma 74
Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real‐life experience 73
Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort 73
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients 73
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 73
An increased number of individuals with clinically recognized monoclonal B-cell lymphocytosis characterizes a recent database of chronic lymphocytic leukemia Rai stage 0. 73
Tagraxofusp in myeloid malignancies 73
The role of corticosteroids in the current treatment paradigm for myelofibrosis 72
Avatrombopag for the Treatment of Immune Thrombocytopenia 72
Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study 72
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 72
Discovery of a Promising Hydroxyamino-Piperidine HDAC6 Inhibitor via Integrated Virtual Screening and Experimental Validation in Multiple Myeloma 72
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 71
Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity 71
A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy 70
Totale 9.153
Salva come PNG Salva come JPEG
Categoria #
all - tutte 119.426
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 119.426
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 1 0 0
2021/202224 0 2 0 0 2 0 0 6 1 1 5 7
2022/2023442 6 5 3 11 8 5 279 22 19 20 50 14
2023/20241.536 35 36 245 194 97 153 80 48 120 50 67 411
2024/20254.157 179 611 112 151 165 137 88 170 706 355 405 1.078
2025/202614.302 2.053 814 1.195 1.365 2.860 1.008 1.998 827 1.008 1.174 0 0
Totale 20.469